Floatz logo

Doxepin

Hypopharyngeal Carcinoma

Mayo ClinicSmall moleculePhase 2Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Hypopharyngeal Carcinoma cohort.

Asset / SponsorPhaseRating
Nivolumab
National Cancer Institute (NCI)
Phase 2CCC
Bms-907351
National Cancer Institute (NCI)
Phase 2CCC
(18F)FPPRGD2
Sanjiv Sam Gambhir
Phase 1/2CCC
FLUDEOXYGLUCOSE
Sanjiv Sam Gambhir
Phase 1/2CCC
Pembrolizumab
VM Oncology, LLC
Phase 1/2CCC
BENZOIC ACID, 4-((4-AMINO-3-(4-CYCLOHEXYL-1-PIPERAZINYL)-9,10-DIHYDRO-9,10-DIOXO-1-ANTHRACENYL)AMINO)-
VM Oncology, LLC
Phase 1/2CCC
Docetaxel
National Cancer Institute (NCI)
Phase 1/2CCC
SX682
National Cancer Institute (NCI)
Phase 1/2CCC

Same molecule, other indications

Doxepin is also rated in:

depressive disorderDormant
CC
Indicative ·
43 / 100
View asset →
dementiaDormant
CC
Indicative ·
43 / 100
View asset →
physiological malfunction arising from mental factorDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →